Manyo Factory Valuation
Is A439090 undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
3/6Valuation Score 3/6
Below Fair Value
Significantly Below Fair Value
Price-To-Earnings vs Peers
Price-To-Earnings vs Industry
Price-To-Earnings vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of A439090 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: A439090 (₩16270) is trading below our estimate of fair value (₩109708.83)
Significantly Below Fair Value: A439090 is trading below fair value by more than 20%.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for A439090?
Key metric: As A439090 is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.
| What is A439090's PE Ratio? | |
|---|---|
| PE Ratio | 16.5x |
| Earnings | ₩16.11b |
| Market Cap | ₩266.47b |
| Key Statistics | |
|---|---|
| Enterprise Value/Revenue | 1.4x |
| Enterprise Value/EBITDA | 9.2x |
| PEG Ratio | 0.3x |
Price to Earnings Ratio vs Peers
How does A439090's PE Ratio compare to its peers?
| Company | Forward PE | Estimated Growth | Market Cap |
|---|---|---|---|
| Peer Average | 15.9x | ||
A237880 CLIO CosmeticsLtd | 8.5x | 11.8% | ₩306.2b |
A092730 NeoPharm | 8.1x | 18.1% | ₩181.1b |
A234690 GREEN CROSS WellBeing | 23.1x | n/a | ₩155.0b |
A214420 Tonymoly | 23.8x | 52.0% | ₩143.7b |
A439090 Manyo Factory | 16.5x | 54.6% | ₩266.5b |
Price-To-Earnings vs Peers: A439090 is expensive based on its Price-To-Earnings Ratio (16.5x) compared to the peer average (15.9x).
Price to Earnings Ratio vs Industry
How does A439090's PE Ratio compare vs other companies in the KR Personal Products Industry?
| 1 Company | Price / Earnings | Estimated Growth | Market Cap |
|---|---|---|---|
A900120 CXI Healthcare Technology Group | 0.7x | n/a | US$15.62m |
| 1 Company | Estimated Growth | Market Cap |
|---|
Price-To-Earnings vs Industry: A439090 is expensive based on its Price-To-Earnings Ratio (16.5x) compared to the KR Personal Products industry average (16x).
Price to Earnings Ratio vs Fair Ratio
What is A439090's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
| Fair Ratio | |
|---|---|
| Current PE Ratio | 16.5x |
| Fair PE Ratio | 26.4x |
Price-To-Earnings vs Fair Ratio: A439090 is good value based on its Price-To-Earnings Ratio (16.5x) compared to the estimated Fair Price-To-Earnings Ratio (26.4x).
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Analyst Forecast: Insufficient data to show price forecast.
Discover undervalued companies
NeoPharm
₩181.1b
Engages in the manufacturing and sale of skin care products in South Korea.
A092730
₩11,580.00
7D
-11.4%
1Y
2.7%
NOVAREXLtd
₩135.1b
Manufactures, wholesales, and retails health and functional foods in South Korea and internationally.
A194700
₩7,630.00
7D
-4.9%
1Y
-30.8%
VT
₩1.0t
Produces and exports laminating machines and films worldwide.
A018290
₩28,900.00
7D
-6.6%
1Y
61.2%